Array Biopharma (ARRY) Stock: Gaining Big On Clinical Data

Array Biopharma Inc (NASDAQ: ARRY)

Today is likely to be a very interesting day in the market following the Trump win. Nonetheless, Array Biopharma is skyrocketing, and for good reason. Today, we’ll talk about what we’re seeing from the stock, why, and what we can expect to see from ARRY ahead. So, let’s get right to it…




What We’re Seeing From ARRY

As mentioned above, Array Biopharma is having an incredibly strong day in the market. In pre-market trading, the stock made its way well into the green, and, at the moment, it looks like gains are likely to continue. Currently (10:05), ARRY is trading at $6.64 per share after a gain of $0.58 per share (9.57%) thus far today.

Why The Gains Are Happening

As usual, when we noticed that ARRY was headed up. The CNA Finance team started to do some digging to see what was causing the move. It didn’t take long to dig the cause up. The gains are the result of new clinical data that’s being made available.

For some time now, Array Biopharma has been testing a combination treatment including Binimetinib and encorafenib. Recently, we learned that the clinical study met its primary endpoint. ARRY showed statistically significant results in an advantage on median progression free survival rates of 14.9 months, compared to 7.3 months with the current standard of care.

What We Can Expect To See Ahead

Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from ARRY. At the end of the day, the company has proven that a treatment it is working on is effective. That means that the treatment will likely lead to great things ahead. All in all, I’m expecting to see gains!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required



[adrotate group=”4″]



[Image Courtesy of Wikipedia]

Leave a Comment